EVALUATION OF CYTOTOXIC EFFECTS OF SELECTIVE INHIBITOR ABEMACICLIB CDK4/6 ON LUNG CANCER CELL LINE (A549) AND GASTRIC CANCER CELL LINE (AGS)

Background & Aim:

Cancer is one of the serious health problems of today's societies, and extensive efforts are being made to deal with it. Nevertheless, in many cases, cancer cells can finally deal with the provided treatment solutions and even sometimes, with the emergence of resistance to chemotherapy, they can benefit from the treatments used for faster tumor growth. Currently, there are several specific CDK4/6 inhibitors such as Palbociclib, Ribociclib, Abemaciclib, and these specific inhibitors significantly reduce tumorigenesis, growth, and tumor invasion. The aim of this study was to investigate the cytotoxicity of Abemaciclib drug on the growth rate and ROS production in two cancer cell lines, A549 and AGS.

Materials & Methods:

In this experimental study, AGS (gastric cancer) and 549A (lung cancer) cell lines were cultured. Cell viability was measured by MTT test and oxygen free radical production rate by ROS test to check the sensitivity of Abemaciclib drug in doses of 1, 2.5, 5, 10, 20 μM in specified cell lines. The data was analyzed with Graph Pad Prism v.:8 software and P<0.05 was considered as a significant level.

The findings of this study show that Abemaciclib can be used as a therapeutic agent in these two cancers, because with the increase in drug concentration, the growth of the target cancer cells decreased.

The results obtained from this study showed that Abemaciclib significantly reduced cell survival and proliferation in (549A) and (AGS) cell lines compared to the control at doses of 10 and 20 μM. More laboratory and animal studies are needed to investigate the exact molecular and clinical processes of Abemaciclib.